Characterization of Clinical Outcomes for Patients with Relapsed High-Risk Neuroblastoma After Autologous Stem Cell Transplant and External Beam Radiotherapy
Patients with relapsed HR-NBL have poor outcomes with median OS < 2 years. Time to relapse was a significant predictor of OS.
Authors
- Jie Jane Chen (ORCID: https://orcid.org/0000-0002-5380-4825)
- Lisa Diller (ORCID: https://orcid.org/0000-0002-4073-5509)
- M. Ioakeim-Ioannidou
- Rochelle Bagatell (ORCID: https://orcid.org/0000-0002-5729-8819)
- S. Terezakis
- Benjamin Lerman (ORCID: https://orcid.org/0000-0001-9973-6779)
- Mary Huang
- S. MacDonald
- Paul J. Catalano (ORCID: https://orcid.org/0000-0002-1105-8852)
- Steve E. Braunstein (ORCID: https://orcid.org/0000-0002-9841-9357)
- Suzanne Shusterman (ORCID: https://orcid.org/0000-0002-5988-1792)
- D. Haas-Kogan
- Kevin Liu (ORCID: https://orcid.org/0000-0002-3012-7921)
- Mathew D. Lin
- Alison M. Friedmann
- Karen Marcus
- Kathryn E. Dusenbery
- Christine E. Hill-Kayser
- Sherif G. Shaaban
- Kieuhoa T. Vo
- Torunn I. Yock
- Hesham Elhalawani
- Steven G. DuBois
Institutions
- University of Minnesota (US)
- Children's Hospital of Philadelphia (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- UCSF Benioff Children's Hospital (US)
- Dana-Farber Brigham Cancer Center (US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2026-02-05
- DOI
- https://doi.org/10.3390/cancers18030520
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00